Status:
UNKNOWN
The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin
Lead Sponsor:
Mackay Memorial Hospital
Conditions:
Type2 Diabetes
Eligibility:
All Genders
20-70 years
Phase:
PHASE4
Brief Summary
The population of type 2 diabetes increased enormously worldwide. As disease progression, uncontrolled type 2 diabetes patients need multiple daily insulin injections, but the risk of body weight gain...
Eligibility Criteria
Inclusion
- Type 2 diabetes patient received premix insulin twice daily and HbA1c\>7%
- \>20 years old
Exclusion
- Type 1 diabetes and gestational diabetes
- Diabetic ketoacidosis in previous 6 months
- Urinary tract infection in previous 6 months
- Pancreatitis in previous 6 months
- estimated GFR\<45 mL/min/1.73m2
- Patient whom already received DPP4 inhibitor or SGLT2 inhibitor
Key Trial Info
Start Date :
September 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 21 2018
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03458715
Start Date
September 21 2017
End Date
November 21 2018
Last Update
March 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital
Taipei, Taiwan, 10449